- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
National Diagnostics to merge with AES
Brandon, FL-based imaging services chain National Diagnostics has signed a definitive agreement to merge with integrated delivery system firm American Enterprise Solutions of Tampa, FL. Under the terms of the agreement, NDI shareholders will maintain a
Brandon, FL-based imaging services chain National Diagnostics has signed a definitive agreement to merge with integrated delivery system firm American Enterprise Solutions of Tampa, FL. Under the terms of the agreement, NDI shareholders will maintain a 12.3% interest in the new company, with AES shareholders holding an 87.7% interest. The combined company will have projected 1998 pre-tax profits of $4.5 million on revenues of roughly $46 million, according to the firms.
NDI agreed to the merger after suffering financial difficulties related to the company's rapid expansion. NDI had fallen behind on payments to vendors and lessors, and the firm's stock was delisted from the NASDAQ exchange in August 1997. AES was founded in September 1997 with the goal of acquiring companies to create community healthcare delivery systems.
In other NDI news, Jugal Taneja has resigned his post as chairman and CEO. COO Curtis Alliston has assumed the role of acting CEO.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.
